Tango Therapeutics (TNGX) to Release Quarterly Earnings on Monday

Tango Therapeutics (NASDAQ:TNGX) will likely be announcing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.3182) per share and revenue of $0.50 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:00 AM ET.

Tango Therapeutics (NASDAQ:TNGX) last issued its earnings results on Thursday, March 5th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.02. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 50.30%. On average, analysts expect Tango Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tango Therapeutics Stock Performance

Shares of NASDAQ:TNGX opened at $19.26 on Friday. The firm has a market cap of $2.75 billion, a PE ratio of -22.14 and a beta of 1.76. The firm’s 50 day simple moving average is $14.29 and its 200-day simple moving average is $10.68. Tango Therapeutics has a one year low of $1.03 and a one year high of $21.82.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Guggenheim increased their price objective on Tango Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. HC Wainwright lifted their target price on Tango Therapeutics from $13.00 to $27.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Jefferies Financial Group reiterated a “buy” rating and issued a $18.00 target price on shares of Tango Therapeutics in a report on Thursday, March 5th. Piper Sandler increased their price target on Tango Therapeutics from $11.00 to $14.00 and gave the stock an “overweight” rating in a research report on Friday, January 16th. Finally, Stifel Nicolaus raised their price target on Tango Therapeutics from $15.00 to $24.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $19.50.

Insider Transactions at Tango Therapeutics

In other news, CFO Daniella Beckman sold 10,317 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total transaction of $126,486.42. Following the transaction, the chief financial officer directly owned 184,297 shares in the company, valued at approximately $2,259,481.22. This trade represents a 5.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Adam Crystal sold 12,000 shares of Tango Therapeutics stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $20.11, for a total transaction of $241,320.00. Following the transaction, the insider directly owned 112,622 shares in the company, valued at approximately $2,264,828.42. The trade was a 9.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 145,884 shares of company stock valued at $1,965,942. Company insiders own 7.50% of the company’s stock.

Institutional Trading of Tango Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TNGX. Global Retirement Partners LLC purchased a new position in shares of Tango Therapeutics in the 4th quarter valued at $35,000. Legal & General Group Plc lifted its stake in shares of Tango Therapeutics by 30.7% during the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after purchasing an additional 1,640 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Tango Therapeutics by 461.3% during the third quarter. Russell Investments Group Ltd. now owns 7,729 shares of the company’s stock valued at $65,000 after purchasing an additional 6,352 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Tango Therapeutics by 44.3% during the second quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock valued at $49,000 after purchasing an additional 2,907 shares in the last quarter. Finally, Northeast Financial Consultants Inc purchased a new position in Tango Therapeutics in the second quarter valued at about $51,000. Institutional investors own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.